Artemisinin Combination Therapy Market Size, Share & Trends Analysis Report and Segment Forecast, 2025| Grand View Research, Inc
“The artemisinin combination therapy market size was valued at USD 363.8 million in 2017. It is projected to expand at a CAGR of 8.5% during the forecast period.”
The global Artemisinin Combination Therapy (ACT) Market size is expected to reach USD 697.9 million by 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 8.5% during the forecast period. Rising adoption rate of ACTs coupled with growing government initiatives to combat malaria epidemic is anticipated to stoke the growth of the market. Furthermore, expanding pipeline and new product approvals are driving the market. Currently, 6 ACTs are recommended by WHO for the treatment of uncomplicated malaria, which are Artemether-Lumefantrine (AL), artesunate-amodiaquine, Artesunate-Mefloquine (AS-AQ), DihydroartemisininPiperaquine (DHA-PPQ), Artesunate-Sulfadoxine-Pyrimethamine (AS-SP), and Pyronaridine-Artesunate (PR-AS). Some of the benefits provided by ACTs are high efficacy and reduced likelihood of developing resistance. Over the years, access to artemisinin combination therapy has expanded considerably. In 2016, ACTs were used as first-line treatment in almost 80 countries. Increasing R & D initiatives by pharma-emerging countries such as India and China are revving up the adoption rate of ACTs. Rising demand from malaria endemic countries such as Kenya, Uganda, Nigeria, and Congo is poised to augment the market. Pipeline for new antimalarial drugs is widening and some of them have been introduced recently. These are some of the factors that are propelling the ACT market. WHO states the necessity for treating uncomplicated malaria, the most serious form of the disease, with ACTs as they are the best treatment available. ACTs are recommended over other treatments including Sulfadoxine-
Follow Us:
pyrimethamine, chloroquine, and artemisinin monotherapies, because parasites have developed resistance to these medicines. Malaria is one of the most distressing diseases across the globe with more than 200 million new cases reported each year. According to Medicines Malaria Venture (MMV), a total of 445,000 deaths were caused by malaria worldwide in 2016. Malaria epidemic is continuing to increase globally and climate change is projected to fuel the trend. To request a sample copy or view summary of this report, click the link below: https://www.grandviewresearch.com/industry-analysis/artemisinin-combination-therapy-act-market Further key findings from the report suggest:
AL was the largest segment in 2017 due to the fact that it was the first ACT to be marketed and prequalified by WHO for its efficacy, safety, and quality. It is available in more than 60 countries and is the only ACT approved by U.S. FDA
MEA held the largest share in the market for ACTs due to growing initiatives by government and nongovernment organizations to raise awareness
Asia Pacific also held a prominent position in the market owing to factors such as large production base of artemisinin herbs coupled with rising access to ACT in this region
Major players operating in the market are Novartis, Sanofi, Cipla, Ajanta Pharma, Ipca Laboratories, Guilin Pharmaceuticals, and KPC Pharmaceuticals
Key players are adopting different strategies to increase their market share such as increasing geographic presence, R & D, new product development, and indication extension.
Grand View Research has segmented the global artemisinin combination therapy market on the basis of type and region: Artemisinin Combination Therapy Type Outlook (Revenue, USD Million, 2014 - 2025)
Artemether-Lumefantrine
Artesunate-Amodiaquine
Dihydroartemisinin-Piperaquine
Artesunate-Mefloquine
Artesunate-Sulfadoxine-Pyrimethamine
Pyronaridine-Artesunate
Artemisinin Combination Therapy Regional Outlook (Revenue, USD Million, 2014 - 2025)
Follow Us:
Asia Pacific o
China
o
India
o
Pakistan
o
Indonesia
o
Vietnam
Latin America o
Brazil
o
Colombia
Middle East & Africa
Follow Us:
o
Nigeria
o
Democratic Republic of Congo
o
Mali
o
Uganda
o
Kenya
Table of Content of Artemisinin Combination Therapy Market Chapter 1 Research Methodology & Scope 1.1 Information Procurement 1.1.1 Purchased database: 1.1.2 GVR’s internal database 1.2 Research Methodology 1.3 Geographic Scope & Assumptions 1.4 Region-wise Market Calculation 1.4.1 Region-wise market: Base estimates 1.4.2 Global market: CAGR calculation 1.5 Region-based Segment Share Calculation 1.6 List of Secondary Sources Chapter 2 Executive Summary 2.1 Market Snapshot Chapter 3 Market Variables, Trends & Scope 3.1 Market Segmentation & Scope 3.2 Market Driver Analysis 3.2.1 Rising Demand for Artemisinin Combination Therapy (ACT) 3.2.2 Strong product pipeline 3.2.3 Rising Government Initiatives 3.3 Market restraint analysis 3.3.1 Limited number of global manufacturers 3.4 Penetration & growth prospect mapping 3.5 ACT - SWOT Analysis, By Factor (political & legal, economic and technological) 3.6 Industry Analysis - Porter’s Chapter 4 Artemisinin Combination Therapy (ACT) Market: Type Outlook 4.1 ACT market by type, movement analysis 4.2 Artemether-Lumefantrine 4.2.1 Artemether-Lumefantrine Market estimates and forecast, 2014 - 2025 (USD Million) 4.3 Artesunate-Amodiaquine 4.3.1 Artesunate-Amodiaquine Market estimates and forecast, 2014 - 2025 (USD Million)
Follow Us:
4.4 Dihydroartemisinin-Piperaquine 4.4.1 Dihydroartemisinin-Piperaquine Market estimates and forecast, 2014 - 2025 (USD Million) 4.5 Artesunate-Mefloquine 4.5.1 Artesunate-Mefloquine Market estimates and forecast, 2014 - 2025 (USD Million) 4.6 Artesunate-Sulfadoxine-Pyrimethamine 4.6.1 Artesunate-Sulfadoxine-Pyrimethamine Market estimates and forecast, 2014 - 2025 (USD Million) 4.7 Pyronaridine-Artesunate 4.7.1 Pyronaridine-Artesunate Market estimates and forecast, 2014 - 2025 (USD Million) Chapter 5 Artemisinin Combination Therapy (ACT) Market: Regional Outlook 5.1 ACT market share by region, 2017 & 2025 (USD Million) 5.2.1 Asia Pacific 5.2.2 China 5.2.3 India 5.2.4 Pakistan 5.2.5 Indonesia 5.2.6 Vietnam 5.2 Latin America 5.2.1 Brazil 5.2.2 Colombia 5.3 MEA 5.3.1 Nigeria 5.3.2 Democratic Republic of Congo 5.3.3 Mali 5.3.4 Uganda 5.3.5 Kenya 5.4 RoW Chapter 6 Competitive Landscape 6.1 Strategy Framework 6.2 Market Participation Categorization 6.2.1 Company Profiles 6.2.2 KPC Pharmaceuticals, Inc
Follow Us:
6.2.2.1 Company overview 6.2.2.2 Financial performance 6.2.2.3 Product benchmarking 6.2.2.4 Strategic initiatives 6.2.3 Guilin Pharmaceutical Co., Ltd 6.2.3.1 Company overview 6.2.3.2 Financial performance 6.2.3.3 Product benchmarking 6.2.3.4 Strategic initiatives 6.2.4 Sanofi 6.2.4.1 Company overview 6.2.4.2 Financial performance 6.2.4.3 Product benchmarking 6.2.4.4 Strategic initiatives 6.2.5 Desano Inc. 6.2.5.1 Company overview 6.2.5.2 Financial performance 6.2.5.3 Product benchmarking 6.2.5.4 Strategic initiatives 6.2.6 Calyx Chemicals & Pharmaceutical Ltd. 6.2.6.1 Company overview 6.2.6.2 Financial performance 6.2.6.3 Product benchmarking 6.2.6.4 Strategic initiatives 6.2.7 Mylan N.V 6.2.7.1 Company overview 6.2.7.2 Financial performance 6.2.7.3 Product benchmarking 6.2.7.4 Strategic initiatives 6.2.8 Novartis AG 6.2.8.1 Company overview
Follow Us:
6.2.8.2 Financial performance 6.2.8.3 Product benchmarking 6.2.8.4 Strategic initiatives 6.2.9 DENK PHARMA GmbH & Co.KG 6.2.9.1 Company overview 6.2.9.2 Financial performance 6.2.9.3 Product benchmarking 6.2.9.4 Strategic initiatives 6.2.10 Hovid-Integrated Global Pharmaceutical Partner 6.2.10.1 Company overview 6.2.10.2 Financial performance 6.2.10.3 Product benchmarking 6.2.10.4 Strategic initiatives 6.2.11 Ipca Laboratories Ltd. 6.2.11.1 Company overview 6.2.11.2 Financial performance 6.2.11.3 Product benchmarking 6.2.11.4 Strategic initiatives 6.2.12 Shelys Africa Pharmaceuticals Ltd. 6.2.12.1 Company overview 6.2.12.2 Financial performance 6.2.12.3 Product benchmarking 6.2.12.4 Strategic initiatives 6.2.13 Cipla Inc. 6.2.13.1 Company overview 6.2.13.2 Financial performance 6.2.13.3 Product benchmarking 6.2.13.4 Strategic initiatives
Follow Us:
About Us: Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact: Sherry James Corporate Sales Specialist, USA Grand View Research, Inc Phone: 1-415- 349-0058 Toll Free: 1-888- 202-9519 Email:
[email protected] For More Information: https://www.grandviewresearch.com Blog: https://healthcareforecastreport.blogspot.com/
Follow Us:
